Back to search results

DCE-MRI for Pancreatic Cancer Treatment Assessment

This study is looking at how well a special type of MRI, called dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), can help doctors understand if treatment is working for patients with borderline resectable pancreatic cancer. This is a type of pancreatic cancer that might be able to be removed by surgery after treatment. You would receive standard treatments like fluorouracil, oxaliplatin, irinotecan, and leucovorin, or gemcitabine and nab paclitaxel. Researchers want to see if DCE-MRI, along with standard evaluations, can predict how many patients can have their tumors completely removed (R0 resection rate). The study aims to enroll 50 participants.

Study design
This is an interventional study with an unclear status, planning to enroll 50 participants. It is not specified if it is randomized or blinded.
What's involved
You would undergo DCE-MRI scans before treatment, about 6 weeks after starting treatment, and again before surgery. You would also have CT scans and blood draws throughout the study.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, R0 resection rate, is measured at the time of surgery. Further follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07705919

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

Not Yet Recruiting
PHASE1Ages 18+InterventionalDiagnostic
Ohio State University Comprehensive Cancer Center
~50 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed TomographyDynamic Contrast-Enhanced Magnetic Resonance ImagingFluorouracilGadolinium-ChelateGemcitabine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
R0 resection rate
Measured over At time of surgery

Conditions

Borderline Resectable Pancreatic Ductal Adenocarcinoma

Explore related trials

Pancreatic Adenocarcinoma

NCT07705919

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohiostudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Harrison Kim, MBA, PhD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center

Who to contact

The Ohio State University Comprehensive Cancer Center
[email protected]
800-293-5066
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
Age ≥ 18 years at the time of consent
Patients have Eastern Cooperative Group (ECOG) performance status of 0-2
Histological or cytological evidence of pancreatic adenocarcinoma
Patients must have borderline resectable primary tumor per National Comprehensive Cancer Network (NCCN) definitions version 2.2025 based on contrast-enhanced CT or MRI (CT or MRI without contrast as part of positron emission tomography \[PET\]/CT or PET/MRI is NOT acceptable; CT or MRI with contrast as part of PET/CT or PET/MRI is acceptable) of the chest, abdomen, and pelvis, where borderline resectable is defined as all of the following:
Solid tumor involvement of ≤ 180° with the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery).
Solid tumor involvement of \> 180° with the portal vein and/or superior mesenteric vein, and a patent portal vein/splenic vein confluence.
Solid tumor contact with the inferior vena cava.
Absence of metastatic disease
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 for solid tumors within 28 days prior to registration
Patients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer
Absolute neutrophil count (ANC) ≥ 1.5×109/L (obtained within 28 days prior to registration)
Platelet count ≥ 100,000/mm3 (100 × 109/L) (obtained within 28 days prior to registration)
Hemoglobin (Hgb) ≥ 8 g/dL (obtained within 28 days prior to registration)
Aspartate transaminase (AST), serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT), serum glutamic-pyruvic transaminase (SGPT) ≤ 3 × upper limit of normal range (ULN) (obtained within 28 days prior to registration)
Total bilirubin ≤ 2 × ULN (obtained within 28 days prior to registration)
Females of childbearing potential must have a negative pregnancy test (serum or urine) within 3 days prior to registration
Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study, and for 6 months after the last dose of study drug(s). Males must be willing to abstain from vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study, and for 3 months after the last dose of study drug(s)
As determined by the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study
History of HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial
Co-enrollment on a non-interventional therapeutic trial is allowed. This includes observational trials and biomarker collection trials

Exclusion

Evidence of distant metastasis
History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation, or dyspnea)
History of arrhythmia that is symptomatic or requires treatment. However, patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial
Patient with a history of allergy or hypersensitivity to any of the study drugs or any of their excipients
Pregnant or lactating
NOTE: breast milk cannot be stored for future use while the mother is being treated in this study
Patient with any other concurrent severe and/or uncontrolled medical condition that would, in the investigators' judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study, or compromise compliance with the protocol (e.g., chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infections, etc.)
No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free and treatment-free for at least two years
Patient who is unwilling or unable to comply with study procedures

What this trial measures

  • R0 resection rateAt time of surgery

    Will be calculated as the proportion of patients achieving R0 resection among evaluable participants, along with a 90% confidence interval based on the binomial distribution. Comparisons of R0 resection rates between the prospective cohort and the matched control group will be conducted using Fisher's exact test.